Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
Huntington's disease is the result of a long polyglutamine tract in the gene encoding huntingtin protein, which in turn causes a large number of cellular changes and ultimately results in neurodegeneration of striatal neurons. Although many theories have been proposed, the precise mechanism by...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0145333&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722930901024768 |
|---|---|
| author | Sayani Dasgupta Michael A Fishman Hana Mahallati Leandro M Castro Alexandre K Tashima Emer S Ferro Lloyd D Fricker |
| author_facet | Sayani Dasgupta Michael A Fishman Hana Mahallati Leandro M Castro Alexandre K Tashima Emer S Ferro Lloyd D Fricker |
| author_sort | Sayani Dasgupta |
| collection | DOAJ |
| description | Huntington's disease is the result of a long polyglutamine tract in the gene encoding huntingtin protein, which in turn causes a large number of cellular changes and ultimately results in neurodegeneration of striatal neurons. Although many theories have been proposed, the precise mechanism by which the polyglutamine expansion causes cellular changes is not certain. Some evidence supports the hypothesis that the long polyglutamine tract inhibits the proteasome, a multiprotein complex involved in protein degradation. However, other studies report normal proteasome function in cells expressing long polyglutamine tracts. The controversy may be due to the methods used to examine proteasome activity in each of the previous studies. In the present study, we measured proteasome function by examining levels of endogenous peptides that are products of proteasome cleavage. Peptide levels were compared among mouse striatal cell lines expressing either 7 glutamines (STHdhQ7/Q7) or 111 glutamines in the huntingtin protein, either heterozygous (STHdhQ7/Q111) or homozygous (STHdhQ111/Q111). Both of the cell lines expressing huntingtin with 111 glutamines showed a large reduction in nearly all of the peptides detected in the cells, relative to levels of these peptides in cells homozygous for 7 glutamines. Treatment of STHdhQ7/Q7 cells with proteasome inhibitors epoxomicin or bortezomib also caused a large reduction in most of these peptides, suggesting that they are products of proteasome-mediated cleavage of cellular proteins. Taken together, these results support the hypothesis that proteasome function is impaired by the expression of huntingtin protein containing long polyglutamine tracts. |
| format | Article |
| id | doaj-art-485f4f8a08234278ba9c7ce9dbb9178d |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-485f4f8a08234278ba9c7ce9dbb9178d2025-08-20T03:11:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014533310.1371/journal.pone.0145333Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.Sayani DasguptaMichael A FishmanHana MahallatiLeandro M CastroAlexandre K TashimaEmer S FerroLloyd D FrickerHuntington's disease is the result of a long polyglutamine tract in the gene encoding huntingtin protein, which in turn causes a large number of cellular changes and ultimately results in neurodegeneration of striatal neurons. Although many theories have been proposed, the precise mechanism by which the polyglutamine expansion causes cellular changes is not certain. Some evidence supports the hypothesis that the long polyglutamine tract inhibits the proteasome, a multiprotein complex involved in protein degradation. However, other studies report normal proteasome function in cells expressing long polyglutamine tracts. The controversy may be due to the methods used to examine proteasome activity in each of the previous studies. In the present study, we measured proteasome function by examining levels of endogenous peptides that are products of proteasome cleavage. Peptide levels were compared among mouse striatal cell lines expressing either 7 glutamines (STHdhQ7/Q7) or 111 glutamines in the huntingtin protein, either heterozygous (STHdhQ7/Q111) or homozygous (STHdhQ111/Q111). Both of the cell lines expressing huntingtin with 111 glutamines showed a large reduction in nearly all of the peptides detected in the cells, relative to levels of these peptides in cells homozygous for 7 glutamines. Treatment of STHdhQ7/Q7 cells with proteasome inhibitors epoxomicin or bortezomib also caused a large reduction in most of these peptides, suggesting that they are products of proteasome-mediated cleavage of cellular proteins. Taken together, these results support the hypothesis that proteasome function is impaired by the expression of huntingtin protein containing long polyglutamine tracts.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0145333&type=printable |
| spellingShingle | Sayani Dasgupta Michael A Fishman Hana Mahallati Leandro M Castro Alexandre K Tashima Emer S Ferro Lloyd D Fricker Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. PLoS ONE |
| title | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. |
| title_full | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. |
| title_fullStr | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. |
| title_full_unstemmed | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. |
| title_short | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. |
| title_sort | reduced levels of proteasome products in a mouse striatal cell model of huntington s disease |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0145333&type=printable |
| work_keys_str_mv | AT sayanidasgupta reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT michaelafishman reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT hanamahallati reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT leandromcastro reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT alexandrektashima reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT emersferro reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease AT lloyddfricker reducedlevelsofproteasomeproductsinamousestriatalcellmodelofhuntingtonsdisease |